<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04389424</url>
  </required_header>
  <id_info>
    <org_study_id>1/15</org_study_id>
    <nct_id>NCT04389424</nct_id>
  </id_info>
  <brief_title>Relationship Between Body Composition, Food Consumption, and Micro and Macronutrients With Gene Expression in Breast Cancer</brief_title>
  <acronym>NUTRIBREAST</acronym>
  <official_title>Evaluation of the Relationship Between Drug Therapy, Food Consumption, Body Composition and Plasma Micronutients Levels With the Expression of Genes Related to Metabolism, Aging and Immunity in Women With Breast Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Jalisciense de Cancerologia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Guadalajara</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto Jalisciense de Cancerologia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The protocol involves measurement of 25 hidroxy vitamin D, gene expression of cytochrome and
      vitamin D receptor , endoxifen, tamoxifen, exemestane, and other metobolites related to
      nutrition and endocrine metabolism.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2017</start_date>
  <completion_date type="Anticipated">January 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 15, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Hidroxy Vitamin D Concentration</measure>
    <time_frame>One time after minimum 3 months of tamoxifen, anastrozole or exemestane treatment (endocrine therapy)</time_frame>
    <description>Plasma levels of Hidroxy Vitamin D</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body Composition</measure>
    <time_frame>One time at enroll with at least 3 months of endocrine therapy</time_frame>
    <description>Body composition (bioimpedance)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tamoxifen plasma levels</measure>
    <time_frame>One time. After minimum 3 months of tamoxifen treatment</time_frame>
    <description>Tamoxifen plasma levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anastrozole</measure>
    <time_frame>One time. After minimum 3 months of anastrozole treatment</time_frame>
    <description>Anastrozole plasma levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exemestane</measure>
    <time_frame>One time. After minimum 3 months of exemestane treatment</time_frame>
    <description>Exemestane plasma levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence</measure>
    <time_frame>One time. In recurrence after at least 3 months with endocrine therapy</time_frame>
    <description>Recurrence of breast cancer after endocrine therapy with tamoxifen or aromatase inhibitors</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Food consumption recall 24 hours (ASA 24)</measure>
    <time_frame>At enroll</time_frame>
    <description>Automated Self-Administered Recall System</description>
  </other_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Endocrine Therapy</condition>
  <condition>Endocrine Therapy Adverse Reaction</condition>
  <condition>Vitamin D Deficiency</condition>
  <condition>Nutrition Disorders</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Anastrozole</arm_group_label>
    <description>Breast cancer women with anastrozole treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tamoxifen</arm_group_label>
    <description>Breast cancer women with tamoxifen treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exemestane</arm_group_label>
    <description>Breast cancer women with exemestane treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Basal</arm_group_label>
    <description>Breast cancer women luminal type without any endocrine treatment (at initial diagnosis)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Recurrence</arm_group_label>
    <description>Breast cancer women luminal type with recurrence of disease during endocrine therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamoxifen</intervention_name>
    <description>Use of tamoxifen for breast cancer recurrence prevention</description>
    <arm_group_label>Recurrence</arm_group_label>
    <arm_group_label>Tamoxifen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exemestane</intervention_name>
    <description>Use of exemestane for breast cancer recurrence prevention</description>
    <arm_group_label>Exemestane</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anastrozole</intervention_name>
    <description>Use of anastrozole for breast cancer recurrence prevention</description>
    <arm_group_label>Anastrozole</arm_group_label>
    <arm_group_label>Recurrence</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Basal</intervention_name>
    <description>Initial diagnosis of breast cacner by biopsy or mastectomy</description>
    <arm_group_label>Basal</arm_group_label>
    <other_name>Breast cancer initial diagnosis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Recurrence</intervention_name>
    <description>Breast cancer recurrence under endocrine therapy</description>
    <arm_group_label>Recurrence</arm_group_label>
    <other_name>Breast cancer recurrence under endoctine therapy</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples to obtain serum and DNA
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Mexican breast cancer woman
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Breast cancer women under endocrine therapy or recurrence of disease after endocrine
             therapy

          -  Signed consent

        Exclusion Criteria:

          -  Mental retardation
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>98 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>JOSE ALFONSO CRUZ RAMOS, MD</last_name>
    <phone>1523314886313</phone>
    <email>josealfonsocr@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Instituto Jalisciense de Cancerologia</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>45180</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JOSE ALFONSO CRUZ RAMOS, MD</last_name>
      <phone>1523314886313</phone>
      <email>josealfonsocr@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <link>
    <url>http://www.ijc.gob.mx/</url>
    <description>Instituto Jalisciense de Cancerolog√≠a</description>
  </link>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 7, 2020</study_first_submitted>
  <study_first_submitted_qc>May 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2020</study_first_posted>
  <last_update_submitted>May 11, 2020</last_update_submitted>
  <last_update_submitted_qc>May 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vitamin D</keyword>
  <keyword>Adverse</keyword>
  <keyword>Cytochrome p450</keyword>
  <keyword>VDR</keyword>
  <keyword>Nutrients</keyword>
  <keyword>Gene Expression</keyword>
  <keyword>Tamoxifen</keyword>
  <keyword>Anastrozole</keyword>
  <keyword>Exemestane</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
    <mesh_term>Nutrition Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
    <mesh_term>Exemestane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

